Revolutionizing Cancer Care for Pets: PetCure Oncology Celebrates One-Year Anniversary

CHICAGO–(BUSINESS WIRE)–#PetCure—PetCure
Oncology, the nation’s leader in advanced radiation therapy for
pets, celebrated its one-year anniversary of treating patients this
month. The first veterinary provider to make stereotactic
radiosurgery (SRS) available to pets on a national scale, PetCure
Oncology’s commitment to integrating SRS into veterinary medicine has
been a game changer regarding cancer care for pets.

Since launching its first site at Arizona
Veterinary Oncology in Phoenix in May 2015, PetCure has opened
locations at Care
Center in Cincinnati, Ohio and Veterinary
Radiation and Imaging Center in Clifton, New Jersey, and is weeks
away from opening a fourth location at Lakeshore
Veterinary Specialists in Milwaukee, Wisconsin.

“We know how important pets are to families,” said JoAnn
Stewart, PetCure Oncology chief operating officer. “Sadly, cancer
accounts for nearly 50 percent of all disease-related pet deaths
annually. But over the past year, pets like Sunny, Calvin, Lilly,
Snickers, Addy, Cera and close to 300 other cancer patients have been
successfully treated at a PetCure Oncology site. We call them ‘Pet
Heroes.’ Most of our patients have been dogs, a number of them have
been cats, and we have even treated a goat. We are extremely proud of
what we have accomplished in such a short time to help so many animals.”

The core of PetCure’s success has been built on providing SRS
directly to the veterinary community. SRS is an advanced form of
radiation therapy used for decades in human medicine and has only
recently become available for pets. It offers significant benefits over
conventional radiation therapy (RT) by:

• Offering treatment with the intent to cure cancer rather
  than just ease symptoms
• Enabling treatment of some tumors previously considered inoperable
  – including brain, spine or prostate
• Delivering radiation with sub-millimeter precision in a noninvasive,
  nonsurgical manner
• Minimizing the risks and side effects commonly associated with
  conventional RT
• Requiring only 1-3 treatment sessions as opposed to 15-21

“Pets deserve the same level of quality cancer care that humans
receive,” said Scott
Milligan, PetCure Oncology chief executive officer. “In addition to
the outstanding technology and exceptionally trained and compassionate
team members, our establishment of a Scientific
Advisory Board has been a tremendous innovation for animals. Our
nine-member team of well-respected clinical experts represents the
fields of veterinary and human radiation oncology, medical oncology,
stereotactic radiosurgery, and medical physics. The board has worked
hard to establish data-driven delivery protocols and implement
human-caliber quality-control standards.”

The company has laid out ambitious goals for the near future, including:

• Growth: Opening three more sites in 2016 and at least a half
  dozen in 2017 to continue toward a goal of 30 sites in five years,
  making SRS accessible to every pet owner in the continental United
  States.
• Knowledge: Collecting and analyzing patient treatment data to
  further the science of SRS delivery and veterinary radiation oncology
  in general.
• Education: Teaching the public about treating cancer in
  companion animals and sharing the benefits of SRS with the veterinary
  and pet owner communities remain a top priority.
• Collaboration: Partnering with veterinarians to create greater
  health-care opportunities. A direct consult platform is in
  development, which will allow veterinarians to interact with a team of
  PetCure Oncology’s veterinary radiation oncologists in near-real time.
• Innovation: Continuing to drive the science behind effective
  cancer treatments for pets.

For additional information, visit PetCureOncology.com.

Contacts

PetCure Oncology
JoAnn Stewart, RVT, CVPM – COO
847-275-8600
jstewart@petcureoncology.com